Abstract | AIM: Exploitation of lactoferrin-appended amphotericin B bearing nanoreservoir (LcfPGNP-AmB) for targeted eradication of Leishmania donovani. MATERIALS & METHODS: RESULTS: LcfPGNP-AmB (size, 196.0 ± 5.28 nm; zeta-potential, +21.7 ± 1.52 mV; encapsulation efficiency, ∼89%) showed reduced toxicity, increased protective proinflammatory mediators expression and down-regulation of disease-promoting cytokines. Biodistribution study illustrated preferential accumulation of LcfPGNP-AmB in liver and spleen. LcfPGNP-AmB showed augmented antileishmanial activity by significantly reducing (∼88%) splenic parasite burden of infected hamsters, compared with commercial-formulations. CONCLUSION: Superior efficacy, desired stability and reliable safety of cost-effective LcfPGNP-AmB, suggest its potential for leishmaniasis therapeutics.
|
Authors | Shalini Asthana, Pramod K Gupta, Anil K Jaiswal, Anuradha Dube, Manish K Chourasia |
Journal | Nanomedicine (London, England)
(Nanomedicine (Lond))
Vol. 10
Issue 7
Pg. 1093-109
( 2015)
ISSN: 1748-6963 [Electronic] England |
PMID | 25929567
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Drug Carriers
- Trypanocidal Agents
- Amphotericin B
- Lactoferrin
|
Topics |
- Amphotericin B
(administration & dosage, pharmacokinetics, pharmacology, therapeutic use)
- Animals
- Cell Line
- Cricetinae
- Drug Carriers
(chemistry, metabolism)
- Drug Delivery Systems
- Lactoferrin
(chemistry, metabolism)
- Leishmania donovani
(drug effects)
- Leishmaniasis, Visceral
(drug therapy, parasitology)
- Macrophages
(parasitology)
- Male
- Mice
- Nanoparticles
(chemistry, metabolism, ultrastructure)
- Rats, Wistar
- Spleen
(parasitology)
- Tissue Distribution
- Trypanocidal Agents
(administration & dosage, pharmacokinetics, pharmacology, therapeutic use)
|